Table 4.
Distribution of Response to Chemotherapy with Cyclosporin A Based on Time from Development of Resistance for Patients with Ovarian Cancer.
| Patient no. | Time (mo)a | Chemotherapy | Response |
| 3 | 0 | Carboplatin | CR |
| 35 | 0 | Carboplatin | CR |
| 7 | 0 | Taxol | PR |
| 24 | 0 | Cisplatin | PR |
| 38 | 0 | Carboplatin | PR |
| 26 | 0 | Taxol/Carboplatin | Stable |
| 30 | 0 | Cisplatin | Stable |
| 10 | 0 | Cisplatin | Progression |
| 19 | 0 | Carboplatin | Progression |
| 32 | 0 | Cisplatin | Progression |
| 6 | 0 | Cisplatin | Progression |
| 14 | 2 | Carboplatin | Stable |
| 11 | 2 | Carboplatin | Progression |
| 29 | 2 | Cisplatin | Not evaluable |
| 16 | 3 | Carboplatin | Stable |
| 31 | 3 | Carboplatin | Stable |
| 27 | 3 | Cisplatin | Progression |
| 17 | 4 | Taxol | Stable |
| 4 | 4 | Carboplatin | Stable |
| 34 | 4 | Cisplatin | Stable |
| 22 | 5 | Cisplatin | CR |
| 40 | 5 | Carboplatin | Stable |
| 2 | 5 | Carboplatin | Progression |
| 5 | 5 | Carboplatin | Progression |
| 33 | 5 | Carboplatin | Progression |
| 8 | 6 | Carboplatin | PR |
| 37 | 6 | Cisplatin | Stable |
| 36 | 6 | Cisplatin | Progression |
| 39 | 6 | Carboplatin | Progression |
a
Interval between chemotherapy agent + cyclosporin A and the previous use of the same agent. Time 0 represents addition of cyclosporin A after progression while on the same chemotherapy drug. (CR, complete response; PR, partial response).